Khan A, Lin P, Kamdar N, Peterson M, Mahmoudi E. Potentially preventable hospitalizations and use of preventive services among people with multiple sclerosis: large cohort study, USA. Mult Scler Relat Disord. 2022 Dec;68:104105. doi: 10.1016/j.msard.2022.104105
Kamudoni P, Amtmann D, Johns J, Cook KF, Salem R, Salek S, Raab J, Middleton R, Repovic P, Alschuler KN, von Geldern G, Wundes A, Barrett A, Olayinka-Amao B, Henke C. The validity, responsiveness, and score interpretation of the PROMISnq Physical Function - Multiple Sclerosis 15a short form in multiple sclerosis. Mult Scler Relat Disord. 2022 Jun;62:103753. doi: 10.1016/j.msard.2022.103753
Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2021 Feb;48:102720. doi: 10.1016/j.msard.2020.102720
Penner I-K, McDougall F, Brown TM, Slota C, Doward L, Julian L, Belachew S, Miller D. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020 Aug;43:102207. doi: 10.1016/j.msard.2020.102207
Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017 Dec;148:16-30. doi: 10.1016/j.biomaterials
Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K, Huang L. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials. 2016 Sep;102:239-48. doi: 10.1016/j.biomaterials.2016.06.030
Walker EA, Picker MJ, Granger AL, Dykstra LA. Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. J Pharmacol Exp Ther. 2004 Jul;310(1):150-8.
Chen XH, Rodríguez S, Hawe E, Talmud PJ, Miller GJ, Underhill P, Humphries SE, Day IN. Evidence of admixture from haplotyping in an epidemiological study of UK Caucasian males: implications for association analyses. Hum Hered. 2004;57(3):142-55.
Allen RM, Granger AL, Dykstra LA. The competitive N-methyl-D-aspartate receptor antagonist (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid (LY235959) potentiates the antinociceptive effects of opioids that vary in efficacy at the mu-opioid receptor. J Pharmacol Exp Ther. 2003 Nov 1;307(2):785-92.
Allen RM, Granger AL, Dykstra LA. Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys. J Pharmacol Exp Ther. 2002 Feb 1;300(2):435-41.
Andrews CW, Bennett L, Yu LX. Predicting human oral bioavailability of a compound: development of a novel quantitative structure-bioavailability relationship. Pharm Res. 2000 Jun 1;17(6):639-44.